Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  Swiss Exchange  >  Vifor Pharma    VIFN   CH0364749348


SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector news


share with twitter share with LinkedIn share with facebook
02/24/2020 | 10:35am EDT

Vifor Pharma today announced a strategic partnership with Fresenius Kabi to create a new joint company based in the People's Republic of China expanding its access to the second largest pharmaceutical market in the world2.

The strategic partnership also expands Vifor Pharma's co-operation with the Fresenius Group, as Vifor Fresenius Medical Care Renal Pharma is an already existing joint company with Fresenius Medical Care.

Fresenius Kabi is a global health care company that specializes in medicines and technologies for infusion, transfusion and clinical nutrition. In China the company is among the top 10 multinational pharmaceutical companies, being a market leader in clinical nutrition, anesthesia and nephrology. Fresenius Kabi has about 6,000 employees and multiple manufacturing and development sites in China. Its sales network covers all cities and regions in China. As part of the agreement, Vifor Pharma and Fresenius Kabi will together create a joint company which will focus on marketing, market access and medical affairs activities for the intravenous iron portfolio. The joint company will be 55% owned by Vifor Pharma and 45% by Fresenius Kabi. Fresenius Kabi will be fully responsible for the commercialization of the intravenous iron portfolio in China, covering more than 20,000 anesthesiologists and 25,000 surgeons in more than 2,000 tier 3 hospitals to support PBM as well as working with HCPs for other indications including nephrology.

Etienne Jornod, Executive Chairman at Vifor Pharma commented: 'We are delighted to announce this important strategic collaboration. Fresenius Kabi is an ideal partner, both from a commercial perspective and from a perspective of shared values. Its strong commercial presence in China is very complementary to the targeted therapeutic areas for our intravenous iron portfolio. Bringing our global iron experience into the joint company and combining this with Fresenius Kabi's strong commercial presence in China will give the parties an excellent position to serve the needs of patients and healthcare professionals in this large and growing market.'

Mats Henriksson, CEO of Fresenius Kabi commented: 'This collaboration with Vifor Pharma is an important step in providing a significant number of patients access to vital blood management treatment. Vifor Pharma has a world leading iron deficiency portfolio and combined with our strong foothold and long-term business relationships in China, this partnership will help to better serve the needs of patients and healthcare professionals across China.'

There is a high unmet medical need for Vifor's intravenous iron products in China with the country having the world's largest iron deficiency anaemia (IDA) population with prevalence estimated at 20%3. At present, one of the primary treatments of IDA is a blood transfusion. However, this is not an economical use of blood in a country where, according to the World Health Organisation (WHO), demand is outstripping supply4. WHO instead recommends improving the clinical use of blood to reduce the number of unnecessary blood transfusions. As a world leader in iron deficiency management, Vifor Pharma's intravenous iron therapies offer new high quality, innovative therapeutic options to the medical community in China to allow the more effective management of patient blood and for the treatment of IDA in many other therapeutic areas. Both parties have agreed to not disclose financial terms of the collaboration.

Vifor Pharma Group is a global speciality pharmaceuticals company. It aims to become the global leader in iron deficiency, nephrology and cardio-renal therapies. The company is the partner of choice for pharmaceuticals and innovative patient-focused solutions. Vifor Pharma Group strives to help patients around the world with severe and chronic diseases lead better, healthier lives. The company develops, manufactures and markets pharmaceutical products for precision patient care. Vifor Pharma Group holds a leading position in all its core business activities and consists of the following companies: Vifor Pharma; Vifor Fresenius Medical Care Renal Pharma (a joint company with Fresenius Medical Care) and OM Pharma. Vifor Pharma Group is headquartered in Switzerland, and listed on the Swiss Stock Exchange (SIX Swiss Exchange, VIFN, ISIN: CH0364749348).

Piao J, Lai J, Yin S, Xu J, Xu Q & Yang X. (2005). Study on the anemia status of Chinese population. Acta Nutr. Sini. 27:268-271.

The Global Use of Medicine in 2019 and Outlook to 2023 (https://iqvia.com)

Piao J, Lai J, Yin S, Xu J, Xu Q & Yang X. (2005). Study on the anemia status of Chinese population. Acta Nutr. Sini. 27:268-271.


Tel: +41 79 957 96 73

(C) 2020 Electronic News Publishing, source ENP Newswire

Stocks mentioned in the article
ChangeLast1st jan.
FRESENIUS MEDICAL CARE AG & CO. KGAA 3.11% 69.14 Delayed Quote.3.21%
VIFOR PHARMA -0.69% 100.85 Delayed Quote.-42.43%
share with twitter share with LinkedIn share with facebook
All news about VIFOR PHARMA
10/21Vifor Pharma and Cara Therapeutics sign US license agreement for IV Korsuva t..
10/20VIFOR PHARMA : and Cara Therapeutics sign US license agreement for i.v. Korsuva&..
09/25VIFOR PHARMA : announces outcome of AFFIRM-AHF topline data
09/24VIFOR PHARMA : announces outcome of AFFIRM-AHF topline data
09/18GLOBAL MARKETS LIVE : Tiktok, CaixaBank, ModernaÖ
09/18VIFOR PHARMA GROUP : Announces Successful Sale of OM Pharma
09/01VIFOR PHARMA : Appoints Gregory Oakes as President North America and Member of t..
08/06VIFOR PHARMA GROUP : Reports Continued Growth in H1 2020
05/19VFMCRP and ChemoCentryx announce topline data from phase-II LUMINA-1 trial of..
05/19CHEMOCENTRYX : and VFMCRP Announce Topline Data from Phase II LUMINA-1 Trial of ..
More news
Sales 2020 1 908 M 2 097 M 2 097 M
Net income 2020 260 M 285 M 285 M
Net cash 2020 293 M 322 M 322 M
P/E ratio 2020 25,0x
Yield 2020 1,97%
Capitalization 6 600 M 7 255 M 7 251 M
EV / Sales 2020 3,30x
EV / Sales 2021 2,91x
Nbr of Employees 2 733
Free-Float 71,8%
Duration : Period :
Vifor Pharma Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends VIFOR PHARMA
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 12
Average target price 148,55 CHF
Last Close Price 101,70 CHF
Spread / Highest target 86,8%
Spread / Average Target 46,1%
Spread / Lowest Target 18,0%
EPS Revisions
Stefan Schulze President, Chief Executive & Operating Officer
Jacques Theurillat Chairman
Colin Bond Chief Financial Officer
Klaus Henning Jensen Chief Medical Officer
Etienne Jornod Honorary Chairman
Sector and Competitors
1st jan.Capitalization (M$)
VIFOR PHARMA-42.43%7 255
JOHNSON & JOHNSON-5.12%376 848
ROCHE HOLDING AG-4.22%283 828
PFIZER INC.-7.96%207 994
MERCK & CO., INC.-16.09%197 256
NOVARTIS AG-19.31%180 257